Biomerica Appoints Eric B. Chin To Board Of Directors, Chair Of Audit Committee
Biomerica appoints Eric B. Chin to Board, replacing Cathy Coste and strengthening financial leadership.


Biomerica, Inc., a global biomedical company specializing in diagnostic and therapeutic products, has appointed Eric B. Chin to its Board of Directors, effective June 4, 2025. Mr. Chin will serve as Chairperson of the Audit Committee and as a member of both the Nominating and Corporate Governance Committee and the Compensation Committee.
Mr. Chin is a seasoned financial executive with deep expertise in healthcare and life sciences. He is currently CFO of Akido Labs, a healthcare technology firm emphasizing preventive care, where he recently played a key role in raising $60 million in funding. In addition to his CFO role, Mr. Chin serves as a board member, Treasurer, and Secretary of Rhode Island Primary Care Physicians Corporation. His prior experience includes leadership roles at Astrana Health, Public Storage, and Alexandria Real Estate Equities, and he began his career at Ernst & Young. He is also a Certified Public Accountant.
Mr. Chin succeeds Ms. Cathy Coste, who stepped down from the board on June 4, 2025. Biomerica clarified that her resignation was not due to any disagreement with the company’s operations or governance.

Simantini Singh Deo works on the latest and trending news happening daily in the pharma world.
Plus dans Pharma News
Tous les articles →
Medicus Pharma soumet à la FDA le protocole de Phase 2b/3 pour Teverelix

Fresenius Kabi reçoit une lettre d’avertissement de la FDA après des défaillances d’enquête sur le traitement aseptique dans l’établissement de Melrose Park

Discussion